Brought to you by 
Lynx and Solexa buy Manteia's DNA colony assets
30 Jan 2023
Executive Summary
Genomic analysis companies Lynx Therapeutics and Solexa Ltd. have jointly acquired technology assets for DNA colony generation from the Swiss biotech Manteia Predictive Medicine SA.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Biotechnology
-
Drug Discovery Technologies
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lynx and Solexa buy Manteia's DNA colony assets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice